Teniposide (VM-26) is an epipodophyllotoxin anticancer drug, widely used as a single agent or in combination for the treatment of children with different malignancies (acute lymphoblastic leukemia, lymphomas, neuroblastoma). It is a phase-specific cytotoxic agent inducing premitotic block in the cell cycle by stabilizing the DNA-topoisomerase II complex. The dose-limiting toxicity of the drug is myelosuppression.
Sinkule JA, Stewart CF, Crom WR; Melton ET, Dahl GV et al: Teniposide (VM-26) disposition in children with leukemia. Cancer Res 1984 44: 1235–1237PubMedGoogle Scholar
Rodman JH, Abromowith M, Sinkule JA, et al.: Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987. 5: 1007–14PubMedGoogle Scholar
Stewart CF, Pieper JA, Arbuck SG et al.: Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 1989. 45 (1) 49–55PubMedCrossRefGoogle Scholar
Huang J: Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci 1983. 72: 1368–1369PubMedCrossRefGoogle Scholar